Evidence map›Paper›PMID 35664735›Full record

ArticleFrontiers in oncology2022

Role of GPER1 in the Mechanism of EGFR-TKIs Resistance in Lung Adenocarcinoma.

Zhenhua Li, Yaqiang Pan, Qinghua Liu, Jian Wang, Chang Liu, Laihao Qu, Dingbiao Li

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Zhenhua LiDepartment of Thoracic Surgery, Yan'an Affiliated Hospital of Kunming Medical University, Kunming, China.
Yaqiang PanDepartment of Thoracic Surgery, Yan'an Affiliated Hospital of Kunming Medical University, Kunming, China.
Qinghua LiuDepartment of Thoracic Surgery, Yan'an Affiliated Hospital of Kunming Medical University, Kunming, China.
Jian WangDepartment of Thoracic Surgery, Yan'an Affiliated Hospital of Kunming Medical University, Kunming, China.
Chang LiuDepartment of Thoracic Surgery, Yan'an Affiliated Hospital of Kunming Medical University, Kunming, China.
Laihao QuDepartment of Thoracic Surgery, Yan'an Affiliated Hospital of Kunming Medical University, Kunming, China.
Dingbiao LiDepartment of Thoracic Surgery, Yan'an Affiliated Hospital of Kunming Medical University, Kunming, China.
Kunming Medical University · CNYan'an Hospital Affiliated To Kunming Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have a good clinical efficacy in lung adenocarcinoma harboring activating-mutation EGFR. Such EGFR mutations are more frequently observed in women and non-smokers. EGFR mutations are frequently reported to correlate with estrogen receptor (ER) α and/or β-expressions in lung adenocarcinoma. However, the role of GPER1, a novel G-protein-coupled estrogen receptor, in the estrogen signaling pathway and the association between its expression and EGFR mutation in lung adenocarcinoma are less well understood. Here, we aimed to examine ERα, Erβ, and GPER1 expressions, and to analyze their roles in the mechanism of EGFR-TKIs resistance in lung adenocarcinoma. We report an enhanced cytoplasmic expression of GPER1 in tissue samples. The nuclear GPER1 positively correlated with ER expression while the nuclear and also cytoplasmic expressing GPER1 negatively correlated with ER expression. Further, TKI resistance results in higher cytoplasmic GPER1 expression and decreased ER and nuclear GPER1 expression with evidence for GPER1 translocation to cell surface during the resistance. GPER1 itself is capable of regulating ER expression with concomitant regulation of MAPK signaling, and co-inhibition of GPER1 and ERs attenuates ERK1/2 and Akt phosphorylation. The results were also verified

Indexed as

epidermal growth factor receptorestrogen receptor αestrogen receptor βG protein-coupled estrogen receptor 1lung adenocarcinomatyrosine kinase inhibitor

Identifiers

PMID35664735
PMCPMC9158128
OpenAlexW4280625883

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.